Subcutaneous 5-Azacitidine Treatment of Naturally Occurring Canine Urothelial Carcinoma: A Novel Epigenetic Approach to Human Urothelial Carcinoma Drug Development

PURPOSE: We determined the efficacy, biological activity, pharmacokinetics and safety of the hypomethylating agent 5-azacitidine (Celgene Corp., Summit, New Jersey) in dogs with naturally occurring invasive urothelial carcinoma. MATERIALS AND METHODS: We performed a preclinical phase I trial in dogs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hahn, Noah M., Bonney, Patty L., Dhawan, Deepika, Jones, David R., Balch, Curtis, Guo, Zhongmin, Hartman-Frey, Corie, Fang, Fang, Parker, Heidi G., Kwon, Erika M., Ostrander, Elaine A., Nephew, Kenneth P., Knapp, Deborah W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3508763/
https://ncbi.nlm.nih.gov/pubmed/22099988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2011.09.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados